Corey J. Langer, MD
Dr. Corey J. Langer is a medical oncologist and Director of Thoracic Oncology at the Hospital of the University of Pennsylvania and Abramson Cancer Center in Philadelphia, Pennsylvania. He specializes in the treatment of patients diagnosed with lung cancers and malignant pleural mesothelioma and is particularly effective in the use of targeted treatment protocols that combine radiation therapy and immunotherapeutic drugs.[1]
Dr. Langer is enthusiastic about the progress that has been made in cancer treatment and believes that immunotherapy may eventually allow physicians to abandon platinum-based chemoradiotherapy altogether. He calls himself a “liquid biopsy evangelical” following research that demonstrates that patients who undergo both tissue and liquid biopsies have an increased overall survival rate compared to those who undergo partial or inadequate testing.[3]
Regarding patient care, Dr. Langer says, “Everything we do underscores what I consider our sacred mission; The therapeutic alliance between patients and healthcare providers is absolutely sacrosanct.”[3]
Education and Career
Dr. Langer earned his undergraduate and medical degree at Boston University as part of a unique, six-year combined program. He completed his internship and residency in Internal Medicine at Graduate Hospital in Philadelphia and then completed fellowships in Hematology and Medical Oncology at both the Presbyterian Hospital of the University of Pennsylvania Health System and Temple University Hospital.[1]
Following completion of his medical education and training, he accepted the role of Director of Thoracic Oncology at Fox Chase Cancer Center, then returned to the University of Pennsylvania Health System where he serves as an oncologist, Professor of Medicine at the University of Pennsylvania’s Perelman Medical School, and Clinical Director of Thoracic Oncology in the Abramson Cancer Center.
Dr. Langer is Editor-in-Chief of the International Lung Cancer News and is frequently invited to present at national and international conferences.
Professional Memberships and Activities
Dr. Langer is actively involved in numerous organizations and committees. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer. He is also a fellow of the American College of Physicians and a member of the Definitive and Adjuvant Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Guideline Panel of the American Society for Radiation Oncology. He is the Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG.[3]
Research
Dr. Langer’s research expertise is focused on the maturing role of immunotherapy in advanced non-small cell lung cancer, the role of targeted agents in oncogene-driven non-small cell lung cancer, and new strategies in small cell lung cancer. His clinical trials have focused on unique combinations of modality strategies that integrate radiation and systemic treatment. He is also interested in novel therapeutic venues in thoracic and head and neck cancer and improving outcomes for underserved populations, including older patients and those with compromised performance status.[2]
His recent publications include:[2]
Yegya-Raman N, Friedes C, Lee SH, Iocolano M, Duan L, Wang X, Li B, Aggarwal C, Cohen RB, Su W, Doucette A, Levin WP, Cengel KA, DiBardino D, Teo BK, O’Reilly SE, Sun L, Bradley JD, Xiao Y, Langer CJ, Feigenberg SJ.: Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys S0360-3016(23), August 2023.
Aggarwal C, Maity AP, Bauml JM, Long Q, Aleman T, Ciunci C, D’Avella C, Volpe M, Anderson E, Jones LM, Sun L, Singh AP, Marmarelis ME, Cohen RB, Langer CJ, Amaravadi R.: A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Oncologist 28(7): 644-e564, July 2023.
Aggarwal C, Marmarelis ME, Hwang WT, Scholes DG, McWilliams TL, Singh AP, Sun L, Kosteva J, Costello MR, Cohen RB, Langer CJ, Doucette A, Gabriel PN, Shulman LN, Rendle KA, Thompson JC, Bekelman JE, Carpenter EL.: Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. JCO Precis Oncol. July 2023.
Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D’Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ.: Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System. Clin Lung Cancer 24(5): 474-482, July 2023.
Sun L, Bleiberg B, Hwang WT, Marmarelis ME, Langer CJ, Singh A, Cohen RB, Mamtani R, Aggarwal C: Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer. JAMA Oncol. Page: e231891, June 2023.
Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D’Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME: Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens. Clin Lung Cancer S1525-7304(23): 00124-9, June 2023.
Bou-Samra P, Chang A, Azari F, Kennedy G, Segil A, Guo E, Marmarelis M, Langer C, Singhal S.: Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med. 12(11): 12208-12220, June 2023.
